Table 1.

Assessment of T-cell resopnses to the phosphorylated p53 peptides in HNSCC patients and healthy donors

No.	Sex	Age (y)	Pathological stage	Primary site	No antigen	p-p53S33	anti-HLA-DR mAb	p-p53S37	anti-HLA-DR mAb	TT830-843
					(IFN-g, pg/ml)
1	M	69	T2N0M0	Larynx	<	124 ± 73	<	67 ± 22	<	195 ± 40
2	M	71	T2N0M0	Larynx	<	216 ± 34	<	41 ± 20	<	305 ± 157
3	M	75	T3N2cM0	Oropharynx	<	155 ± 90	<	57 ± 20	<	167 ± 101
4	M	47	T2N0M0	Oropharynx	<	198 ± 89	<	92 ± 39	<	266 ± 163
5	F	79	T2N0M0	Hypopharynx	<	236 ± 95	<	97 ± 32	<	388 ± 86
6	M	37	Normal Volunteer		<	47 ± 5	<	45 ± 7	<	414 ± 296
7	M	34	Normal Volunteer		<	56 ± 7	<	43 ± 3	<	721 ± 401
8	F	52	Normal Volunteer		<	43 ± 5	<	41 ± 11	<	325 ± 133

<: less than the lower limit of detection (mean <30░pg/ml). No. 1–5 are HNSCC patients and No. 6–8 are healthy donors.